# US 2022/0032271 A1 · Crosslinked polysaccharide based absorbents for removal of anti-a and/or anti-b antibodies from human plasma and whole blood > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2022/0032271 A1 - Document ID: US20220032271A1 - Status: Published application - Kind: A1 - Application number: 17/298,968 - Filed: 2019-12-02 - Published: 2022-02-03 - Earliest claimed: 2018-12-05 - Assignees: CytoSorbents Corporation - Applicants: CytoSorbents Corporation - Inventors: Tamaz GULIASHVILI; Maryann GRUDA; Thomas GOLOBISH; David JAMES; Karl-Gustav RUGGEBERG; Pamela O'SULLIVAN; Sarah PATTERSON - Web page: https://patentgrep.com/patent/US20220032271A1 ## CPC - B01J 20/3274: {Proteins, nucleic acids, polysaccharides, antibodies or antigens} - C07K 16/06: from serum - B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography} - B01J 20/28004: {Sorbent size or size distribution, e.g. particle size} - B01J 20/28019: {Spherical, ellipsoidal or cylindrical} - B01J 20/28078: {Pore diameter} - B01J 20/3212: {consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds} - B01J 20/3219: {involving a particular spacer or linking group, e.g. for attaching an active group} - C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes - C07K 16/065: {Purification, fragmentation} - C07K 16/34: against blood group antigens - G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)} - B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention concerns polymeric media based on modified natural polysaccharides for removing one or both of Anti-A Antibodies and Anti-B Antibodies from human blood or plasma, the media comprising one or both of (i) a polymeric solid support with a blood group A Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions, and (ii) a polymeric solid support with a blood group B Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions. ## Claims ### Claim 1 A polymeric media based on modified natural polysaccharides for removing one or both of Anti-A Antibodies and Anti-B Antibodies from human blood or plasma, the media comprising one or both of (i) a polymeric solid support with a blood group A Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions, and (ii) a polymeric solid support with a blood group B Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions. ### Claim 2 (depends on 1) The polymeric media of claim 1 wherein the blood group A Antigen ligand is Anti-A-O—NH2 or Anti-A-S—NH2. ### Claim 3 (depends on 1) The polymeric media of claim 1 wherein the blood group B Antigen ligand is Anti-B-O—NH2 or Anti-B-S—NH2. ### Claim 4 (depends on 1) The polymeric media of claim 1, comprising both of said blood group A Antigen ligand attached to a first polymeric solid support and said blood group B Antigen ligand attached to a second solid support. ### Claim 5 (depends on 1) The polymeric media of claim 1, comprising both of said blood group A Antigen ligand attached to said solid support and said blood group B Antigen ligand attached to said solid support. ### Claim 6 (depends on 1) The polymeric media of claim 1, wherein said solid support, first solid support and second solid support comprise a polymer comprising at least one of cellulose, dextran, starch, agarose, and chitosan. ### Claim 7 (depends on 1) The polymeric media of claim 1, wherein said solid support, first solid support and second solid support comprise a beaded form of functional polysaccharide with a bead size range of 45-1,000 um. And pore size ranging from non-porous to 1-20,000 angstrom pore diameter. ### Claim 8 (depends on 1) The polymeric media of claim 1, wherein said solid support, first solid support and second solid support are functionalized with NaIO4 oxidation followed by secondary crosslinking with appropriate di, tri or polyamines. ### Claim 9 (depends on 7) The polymeric media of claim 7, wherein the crosslinked polysaccharide based beaded material is functionalized with natural or synthetic compounds including peptides, proteins, sugars, polysaccharides, nucleotides, oligonucleotides, lipids and drugs. ### Claim 10 (depends on 1) The polymeric media of claim 1, wherein solid support, are stabilized toward degradation and made stable under wide range of pH (1-14) of the media with partial crosslinking with a di, tri, tetra or polyfunctional primary or secondary amine. ### Claim 11 (depends on 10) The polymeric media of claim 10, wherein the trifunctional amine is tris(2-aminoethyl)amine (TREN). ### Claim 12 (depends on 1) The polymeric media of claim 1, wherein solid support contains partially unreacted aldehyde groups as functional group to be used for coupling of various amino group containing ligands.